Cargando…
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and –experienced patients
BACKGROUND: Telaprevir (TVR) has been approved for response-guided-therapy (RGT) of chronic hepatitis C (HCV) genotype-1-infection in treatment-naïve and –experienced patients. In RGT-regimens patients that did not achieve extended rapid-virological-response (eRVR) within the first 4–12 weeks underg...
Autores principales: | Goralczyk, Armin D, Cameron, Silke, Amanzada, Ahmad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852825/ https://www.ncbi.nlm.nih.gov/pubmed/24118976 http://dx.doi.org/10.1186/1471-230X-13-148 |
Ejemplares similares
-
Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012) -
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012) -
Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
por: Siraj, Dawd S., et al.
Publicado: (2014) -
IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders
por: Calisti, Giorgio, et al.
Publicado: (2015) -
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
por: Wei, Lai, et al.
Publicado: (2018)